A Phase I, Open-label, Multiple-cohort, Dose-escalation Study to Evaluate the Safety and Tolerability of Gene Therapy With RGX-314 in Subjects With Neovascular AMD (nAMD)
Phase of Trial: Phase I
Latest Information Update: 05 Aug 2017
At a glance
- Drugs RGX 314 (Primary)
- Indications Wet age-related macular degeneration
- Focus Adverse reactions
- Sponsors REGENXBIO
- 23 Mar 2017 Status changed from not yet recruiting to recruiting.
- 06 Jan 2017 According to a REGENXBIO media release, the company plans to begin enrollment in the trial in mid-2017 and present interim update from the study in late 2017.
- 06 Jan 2017 According to a REGENXBIO media release, the company has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) during the first week of 2017 to support this study.